TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Two Online Interventions -Watch Your Weight During the Holidays Program and the Relative 5:2 Fasting- for the Prevention of Body Weight Gain at 8 Weeks in Mexican Adults in the Covid-19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Mexican adult participants (≥20 and ≤60 years)~* Residents of the city of Hermosillo, Sonora~* Body Mass Index ≥ 23 kg/m2 and ≤ 40 kg/m2~* Availability and motivation to attend the intervention program~* Committed to not undertake any other intervention in place of, or in combination with, the one assigned in the study during the 8 weeks of the intervention~Exclusion Criteria:~* Diagnosed medical conditions that constitute a contraindication for intervention such as: diabetes, hypertension, diseases with an effect on body weight (for example: liver failure; cancer in treatment or in advanced stage; history of COVID-19 that required hospitalization, supplemental oxygen or has left sequelae that contraindicates the intervention; psychiatric conditions; eating disorders, etc.).~* Use of drugs or substances with an effect on weight, for example, metformin, orlistat, corticosteroids, etc.~* Use of addictive substances such as drugs of abuse~* Previous bariatric surgery.~* Being a participant in another intervention or treatment for the management of obesity.~* Weight loss \> 5% of total body weight in the last 4 months.~* Having plans to become pregnant within the study period, currently pregnant or breastfeeding.~* Another family member has agreed to participate in the study.~* Illiteracy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Watch your Weight During the Holidays Program (Type: ACTIVE_COMPARATOR): None
- Relative 5:2 Fasting (Type: ACTIVE_COMPARATOR): None
- Control Group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* High risk prostate cancer:~  * clinical stage T3 (cT3) prostate cancer or~ * pre-treatment PSA \> 20 or~ * Gleason score\>8 on Trans-Rectal Ultrasound (TRUS) biopsy~* Score of \> 3 on the Vulnerable Elderly Scale or refuses standard radiotherapy + androgen deprivation therapy~* No evidence of extra-prostatic disease on screening bone scan and Computed Tomography (CT) scan (non-contrast CT used for CT simulation acceptable)~* Signed written and voluntary informed consent provided.~* Patients must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures~* Age ≥ 18 years~Exclusion Criteria:~* Patients not meeting the eligibility criteria~* Prior pelvic radiotherapy or brachytherapy~* Use of anti-coagulation (low molecular weight heparin or Coumadin)~* History of inflammatory bowel disease, Crohn's disease, diverticulitis or collagen vascular disease (other than rheumatoid arthritis)~* Previous treatment for malignancy (other than basal or squamous cell skin cancer) within 3 years of prostate cancer diagnosis

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Synbiotics Cohort Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Aged \<13 months~* Confirmed or suspected CMA- based on healthcare professional (HCP) judgement~* At baseline, parent(s) must already be exclusively or partially formula feeding their child (with a hypoallergenic or non-hypoallergenic formula) or have already made the decision to start exclusively or partially formula feeding~* Recently prescribed a hypoallergenic formula containing synbiotics~Exclusion Criteria:~* Exclusively breastfed infants~* Primary lactose intolerance~* Enterally fed infants~* Premature infants (born \<37 weeks) with a corrected age of less than 1 month~* Infants with contraindications to the use of hyopallergenic formula containing synbiotics~* Major hepatic or renal dysfunction~* Investigator concern around the ability of family to comply with protocol and requirements of study

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 13 Months
- Healthy Volunteers: f

Study Arms:
- Hypoallergenic formula containing synbiotics (Type: None): Infants (aged \<13 months) with cow's milk allergy (CMA) who are prescribed a hypoallergenic formula containing synbiotics as part of usual clinical practice for the dietary management of CMA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study on the Effects of Sitaxsentan on Airway Remodeling in Patients With Severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 50 non smoking (25 on active treatment and 25 on placebo) patients with severe asthmatic patients (age over 18 and less than 70) and irreversible airflow obstruction (FEV1≤ 70% of predicted)~Exclusion Criteria:~* Abnormal liver chemistry at inclusion, female without acceptable contraceptive methods

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- sitaxsentan, airway remodeling (Type: PLACEBO_COMPARATOR): Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .
- placebo, airway remodeling (Type: PLACEBO_COMPARATOR): Blinded, randomised placebo-controlled trial involving two parallel groups of severe asthmatic patients with irreversible airflow obstruction (FEV1≤ 70% of predicted) .

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* White Males and females who have given written informed consent.~* Ages 18 through 25;also, patients must weigh ≥40 kg and ≤140 kg.~* Good physical health as determined by a complete physical examination, an EKG within normal limits, and laboratory screening tests within acceptable parameters.~* At least an average of one episode of binge or heavy drinking per week in the past month prior to enrollment. For men and women, that is ≥5 and ≥4 drinks/drinking day, respectively.They also need to report at least one day of heavy drinking within the 7 days prior to randomization.~* The pregnancy test for females at intake must be negative. Additionally, women of childbearing potential must be using an acceptable form of contraception.~* Literate in English and able to read, understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments.~* Answer an advertisement in the newspaper/radio/television, and express a wish to stop heavy drinking.~* Willingness to participate in behavioral treatments to stop heavy drinking~Exclusion Criteria:~Please contact site for additional information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Ondansetron (Type: EXPERIMENTAL): Ondansetron + BASICS Plus
- Placebo (Type: PLACEBO_COMPARATOR): Placebo + BASICS Plus

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes of Slow Developing Blastocysts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All IVF cycles undergoing autologous fresh blastocyst embryo transfer~* All IVF cycles in which the best available embryo for transfer is at expansion grade \<4~* All ages~Exclusion Criteria:~* Ovum Donation cycles~* Preimplantation genetic testing cycles

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 44 Years
- Healthy Volunteers: t

Study Arms:
- Fresh ET (Type: NO_INTERVENTION): The best available embryo is at expansion grade \<4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and transferred regardless of expansion grade. Arrested blastocysts are discarded.
- Frozen Embryo Transfer (Type: EXPERIMENTAL): The best available embryo is at expansion grade \<4 by Gardner classification 5 days after oocyte retrieval. Patient's embryos are cultured to day 6 and vitrified regardless of expansion grade. Arrested blastocysts are discarded. The single best available embryo is transferred under a cryo-synthetic cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient has a carcinoid syndrome defined as ≥3 stools/day and/or ≥3 flushes/week.~* The patient has elevated 5-Hydroxyindoleacetic acid (above upper limit normal).~* The patient has a well-differentiated mid-gut carcinoid tumour or serotonin secreting tumour of unknown localisation with hepatic metastasis.~Exclusion Criteria:~* The patient has undergone surgery related to a neuroendocrine tumour (NET) within 4 weeks prior to study entry or has surgery planned during the study.~* The patient has received short acting somatostatin analogues (SSAs) within 2 weeks before study entry or has received short acting SSAs for more than 3 months.~* The patient has received a radiolabelled SSA at any time before study entry.~* The patient has received long acting SSAs under certain circumstances.~* The patient has previously received any specific anti tumour treatment such as chemotherapy, (chemo)embolisation, radiotherapy or interferon in the last 6 months.~* The patient has signs or symptoms of cardiac insufficiency.~* The patient has an ejection fraction \<40% and/or clinically severe cardiac valvular regurgitation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BIM 23A760 (Type: EXPERIMENTAL): This dose adaptive study is planned to treat up to 20 patients in each starting dose cohort, with a maximum of three starting dose cohorts. The doses planned to be assessed are 1, 2, 4, 6 and 8 mg, however, the maximum starting dose will be 4 mg. The starting dose of the first cohort will be 1 mg; the first cohort will include at least five patients. After the first fifteen patients have been treated for 4 weeks, the results will be reviewed by a Data Review Committee. An extension phase (Part B) is planned for those subjects completing the initial study and fulfilling specific eligibility criteria (symptoms control, willingness to participate, safety and tolerability).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Persistent Innate Immune Activation on Vaccine Efficacy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to receive three doses of an FDA-approved Hepatitis B vaccine~* Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load laboratory studies)~* Healthy volunteer without significant medical problems~Exclusion Criteria:~* Received any vaccine within a month prior to study vaccine~* Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen~* HIV positive~* For HCV-negative, healthy volunteers: History of HCV infection or positive HCV antibody test~* Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study~* In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol~* Any clinically significant abnormality or medical history or physical examination including history of immunodeficiency or autoimmune disease (in addition to HCV infection, for HCV group)~* Currently taking systemic steroids or other immunomodulatory medications including anticancer medications and antiviral medications~* Any clinically significant acute or chronic medical condition requiring care by a primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness, malignancy, substance abuse) that, in the opinion of the investigator, would preclude participation~* Unable to continue participation for 156 weeks~* History of previous Hepatitis B vaccination(s)~* Male or female \< 18 and \> 62 years of age~* Is pregnant or lactating~* History of Hepatitis B infection~* Clinical, laboratory, or biopsy evidence of cirrhosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 62 Years
- Healthy Volunteers: t

Study Arms:
- Recombivax in HCV infected individuals (Type: ACTIVE_COMPARATOR): Recombivax vaccine administered IM to HCV-infected individuals
- Recombivax in healthy volunteers (Type: ACTIVE_COMPARATOR): Recombivax vaccine administered IM to healthy individuals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate Use of Mangosteen Juice Added to Usual Care in Reducing Risk of Recurrent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Candidates for this study must meet all of the following criteria:~  * Age \>18 years~ * Documented atrial fibrillation with a clinically indicated cardioversion.~ * Anticoagulation with therapeutic INR or PTT as per Mayo Clinic cardioversion guidelines.~ * Provision of written informed consent.~Exclusion Criteria:~* Subjects will be excluded if any of the following conditions apply:~  * Presence of atrial fibrillation secondary to a reversible cause such as thyrotoxicosis or alcohol use~ * Myocardial infarction within 1 month, CABG or cardiac surgery including surgical maze or AF radiofrequency ablation within the past 3 months~ * Presence of an implanted pacemaker, atrial defibrillator, or ventricular defibrillator~ * History of bleeding diathesis or coagulopathy~ * Known atrial thrombus or contra-indication to cardioversion~ * Active infection or collagen vascular disease with active inflammation~ * Current use of corticosteroids~ * Gastrointestinal (GI) or genitourinary bleed within the past six months requiring transfusion~ * Concomitant medical illness (i.e., cancer, congestive heart failure) that may preclude protocol compliance, confound data interpretation or limit life-expectancy to less than one year~ * Known allergy to juice components~ * Inability or refusal to cooperate with study procedures~ * Unsuccessful cardioversion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- mangosteen juice (Type: ACTIVE_COMPARATOR): subjects randomized 1:1 to this arm will receive juice containing the mangosteen ingredient
- placebo juice (Type: PLACEBO_COMPARATOR): subjects randomized 1:1 to this arm will receive specially prepared juice not containing mangosteen ingredient

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pre-Prostatectomy Celecoxib or Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically or cytologically proven adenocarcinoma of the prostate and planned prostatectomy~* Age \>= 18~* Performance status (ECOG \<= 2)~* Hemoglobin \> 10 g/dL (within 4 weeks)~* Creatinine \<= 1.5 mg/dL~* Signed informed patient consent~Exclusion Criteria:~* Other preoperative or prior treatment directed at prostate cancer~* Significant active medical illness which in the opinion of the investigator would preclude protocol treatment~* Use of non-steroidal anti-inflammatory agents within seven days of celecoxib treatment~* Hypersensitivity to celecoxib~* A history of asthma, urticaria, or anaphylaxis precipitated by an NSAID~* History of significant upper gastrointestinal bleeding or active peptic ulcer disease~* Current treatment with anticoagulants~* Allergy to sulfonamide

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: ACTIVE_COMPARATOR): Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
- Placebo (Type: PLACEBO_COMPARATOR): Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Severe Acute Malnutrition in CMAM, Nigeria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria (all must be met):~* Age 6-59 months~* Weight-for-height z-score (WHZ) \< -3 SD or mid-upper arm circumference (MUAC) \< 115 mm~* No nutritional or nutritional edema Grade I and II~* Primary residence within catchment area of enrollment site~* Available for full 8-week study~* Has not been admitted to a nutritional program for the treatment of severe acute malnutrition (SAM) in the 2 preceding weeks~* No antibiotic use in past 7 days~* No clinical complications requiring antibiotic treatment~* No clinical complications requiring inpatient treatment~* No congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of SAM treatment benefit (such as cerebral palsy, Down syndrome, congenital heart disease, cleft lip/palate, sickle cell disease, etc)~* No allergy to macrolides/azalides~* Sufficient appetite according to a feeding test with ready-to-use therapeutic food (RUTF)~* Appropriate written informed consent from at least one parent or guardian~Exclusion criteria (any excludes):~* Age \< 6 months or \> 59 months~* WHZ ≥ -3 SD or MUAC ≥ 115 mm~* Primary residence outside catchment area of enrollment site~* Not available for full 8-week study~* Presence of nutritional edema Grade III~* Admission to a nutritional program for the treatment of SAM in the 2 preceding weeks~* Antibiotic use in past 7 days~* Clinical complications requiring antibiotic treatment~* Clinical complications requiring inpatient treatment~* Congenital abnormality or chronic debilitating illness that would lead to predictable growth faltering or reduce likelihood of SAM treatment benefit (such as cerebral palsy, Down syndrome, congenital heart disease, cleft lip/palate, etc)~* Allergy to macrolides/azalides~* Insufficient appetite according to a feeding test with ready-to-use therapeutic food (RUTF)~* Parent or guardian refuses to provide consent

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Azithromycin (Type: EXPERIMENTAL): Children in this arm will receive one dose of amoxicillin.
- Amoxicillin (Type: ACTIVE_COMPARATOR): Children in this arm will receive a 5-day course of amoxicillin (standard care).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy